Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

$AXNX
Medical/Dental Instruments
Health Care
Get the next $AXNX alert in real time by email

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics' existing sacral neuromodulation (SNM) offering.

Physicians determine a patient's eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE). The temporary lead that is placed during a PNE is often done in the office setting without real-time imaging (i.e., fluoroscopy). Due to anatomic variability between patients, locating the appropriate sacral foramen (closest to the desired root of the sacral nerve) can be challenging without fluoroscopy and can hinder physicians' confidence in the procedure. The acquired technology addresses this challenge with an elegant solution comprising a software application and a hardware tool that makes PNE lead placement easier, faster, and more accurate.

The technology has the potential to reduce procedure time and facilitate a more accurate placement which, in turn, can increase physicians' confidence in the SNM procedure and drive increased therapy adoption, utilization and permanent implant conversion rates. With a standard x-ray image of a patient's pelvis, a physician can leverage the software to determine the optimal location for needle entry and lead placement based on the patient's specific anatomy. The technology can readily be implemented into existing clinical workflows as it takes only minutes to use and requires minimal training.

Axonics has acquired the assets of Radian, LLC from Intermed Labs for undisclosed terms. Axonics expects the product to receive FDA clearance and be available on a commercial basis in mid-2024.

"Since Axonics' founding, our SNM development efforts have focused on enhancing the physician and patient experience," said Raymond W. Cohen, chief executive officer of Axonics. "We expect the Radian technology will improve patient comfort, increase physician confidence and SNM access, simplify the learning curve for physicians new to SNM, and increase PNE trial success rates, which should ultimately result in more adults being treated with our life-changing SNM therapy. We are confident that empowering physicians with innovative technology and tools has the potential to drive significant SNM market expansion in the years ahead."

About Intermed Labs

Intermed Labs is an award-winning innovation lab and startup studio that advances technological breakthroughs in health technology. Intermed Labs works with talented physicians, companies, and health systems to conceive, launch, and scale new innovations to improve patient care. For more information, visit www.intermedlabs.com.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.

Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designs," and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics' filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Get the next $AXNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AXNX

DatePrice TargetRatingAnalyst
1/9/2024Outperform → Peer Perform
Wolfe Research
7/19/2023$69.00Outperform
Robert W. Baird
7/13/2023$70.00Overweight
KeyBanc Capital Markets
5/23/2023$75.00Buy
CL King
4/14/2023$75.00Buy
Mizuho
3/24/2023$71.00Hold → Buy
Needham
10/21/2022$85.00Outperform
RBC Capital Mkts
10/12/2022$75.00Hold
Jefferies
More analyst ratings

$AXNX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Boston Scientific Closes Acquisition of Axonics, Inc.

    MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti

    $AXNX
    $BSX
    Medical/Dental Instruments
    Health Care
  • Axonics Reports Third Quarter 2024 Financial Results

    Axonics, Inc. (NASDAQ:AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. "Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year," said Raymond W. Cohen, chief executive officer. "Revenue growth for both sacral neuromodulation and Bulkamid® was driven by higher utilization at existing customers and the onboarding of new accounts." Mr. Cohen continued, "Our commitment to innovation, quality, direct-to-consumer advertising and providing str

    $AXNX
    Medical/Dental Instruments
    Health Care
  • Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

    Axonics, Inc. (NASDAQ:AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15®) and is paired with the same tined lead and intuitive, easy to use patient remote control. The R20

    $AXNX
    Medical/Dental Instruments
    Health Care

$AXNX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AXNX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AXNX
SEC Filings

See more

$AXNX
Leadership Updates

Live Leadership Updates

See more
  • Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

    Kestra Medical Technologies, Inc., a privately held wearable medical device and digital healthcare company, today announced that Raymond W. Cohen has joined the board of directors as a new independent board director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725221367/en/Kestra Medical Technologies, Inc. announced that Raymond W. Cohen has joined the board of directors as a new independent board director. (Photo: Business Wire) Brian Webster, President & CEO of Kestra said, "Ray is one of the most experienced and accomplished leaders in the medical device industry with multiple decades of success in developing and commer

    $AXNX
    Medical/Dental Instruments
    Health Care
  • BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

    BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (NASDAQ:AXNX), an Irvine, Calif. based global medical technology company that he co-founded in 2013 and took public in October 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

    $AXNX
    Medical/Dental Instruments
    Health Care
  • Axonics Announces CFO Retirement and Appoints Successor

    Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. "On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years," said Raymond W. Cohen, chief executive officer. "Dan has played an instrumental role in Axonics' success and the significant value that

    $AXNX
    Medical/Dental Instruments
    Health Care

$AXNX
Financials

Live finance-specific insights

See more
  • Boston Scientific Announces Results for Fourth Quarter and Full Year 2023

    MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.

    $AXNX
    $BSX
    Medical/Dental Instruments
    Health Care
  • Axonics Reports Third Quarter 2023 Financial Results

    Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023. "Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter," said Raymond W. Cohen, chief executive officer. "Our growth was driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. Based on the s

    $AXNX
    Medical/Dental Instruments
    Health Care
  • Axonics to Report Third Quarter 2023 Financial Results on October 30

    Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 3Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 3Q23 webcast. A replay of the webcast will be archived in t

    $AXNX
    Medical/Dental Instruments
    Health Care

$AXNX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more